Alerte De Sécurité sur Trade name: Dimension EXL TSHL Flex, Dimension EXL FT4L Flex, Sirolimus Flex® - Dimension. Technical Name :. ANVISA registration number: 10345161710, 10345161706, 10345161657. Risk class :. Affected model: 200 tests, 120 tests, 4 cartridges. Serial numbers affected: All batches

Selon Agência Nacional de Vigilância Sanitária (ANVISA), ce/cet/cette alerte de sécurité concerne un dispositif en/au/aux/à Brazil qui a été fabriqué par Siemens Healthcare Diagnósticos S.A.; Siemens Healthcare Diagnostics INC..

Qu'est-ce que c'est?

Les alertes fournissent des informations importantes et des recommandations concernant les dispositifs médicaux. Le fait qu'une alerte soit émise ne signifie pas nécessairement qu'un dispositif soit dangereux. Les alertes de sécurité, qui sont envoyées tant aux travailleurs du secteur médical qu'aux utilisateurs de ces dispositifs, peuvent inclure des rappels. Elles peuvent être rédigées par des fabricants mais aussi par des autorités en charge de la santé.

En savoir plus sur les données ici
  • Type d'événement
    Safety alert
  • ID de l'événement
    2417
  • Date
    2017-11-14
  • Pays de l'événement
  • Source de l'événement
    ANVISA
  • URL de la source de l'événement
  • Notes / Alertes
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • Notes supplémentaires dans les données
    Siemens does not recommend retroactive analysis of results based on this occurrence. If you wish to notify technical complaints and adverse events use the following channels: Notivisa: Notices of adverse events (AE) and technical complaints (QT) for products subject to Sanitary Surveillance should be made through the NOTIVISA System. To access the System, you must register and select the Health Professional option, if you are a liberal professional or the Institution / Entity option, if you are a professional of an institution / entity. Technovigilance System: Patient or citizen can notify through the Technovigilance System / SISTEC access through the link Additional information: - Date of identification of the problem by the company: 10/16/2017 - Date of notification notice to Anvisa: 11/14/2017 The company that owns the affected product is responsible for contacting its customers in a timely manner. to ensure the effectiveness of the Field Action in progress. It stands out the joint responsibility of the distribution chain and use of health products in maintaining its quality, safety and efficacy, as well as the effectiveness of the Field Action, expressed by RDC 23/2012: "(...) Art 2 ° A holder of registration of health product is the holder of the registration / registration of health product with Anvisa. Single paragraph. The registration holder, as well as other agents involved from the production to the use of the product, or discarding it when applicable, are jointly and severally responsible for maintaining the quality, safety and efficacy of the health products to the final consumer. Art. 12 Distributors of health products shall forward to the registration holder, in a timely manner, the distribution map and other information requested for the notification and execution of field actions. (...) "
  • Cause
    Siemens healthcare diagnostics sa had notified its clients about biotin interference in the: thyroid stimulating hormone (tsh) test; free thixorine (ft4l) and sirolimus through field action vc 17-04. at present the company informs that the current research has identified the following new information: 1. biotin interference limits are listed incorrectly in the instructions for use of the following tests: dimension tshl, dimension ft4l and dimension vista tsh. biotin concentrations above the concentrations listed in table 2 in the non-interfering biotin revision column may potentially result in interference> 10%. 2. in the dimension vista ctni, mmb, and dimension siro methods, ifus do not contain biotin interference information. biotin concentrations above the concentrations listed in table 2 in the non-interfering biotin revision column may potentially result in interference> 10%.
  • Action
    Field Action Code VC 17-04B triggered under the responsibility of the company Siemens Healthcare Diagnósticos SA It will make Notification to the client.

Manufacturer